| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 11.3 | 10.6 |
| Profit before tax | -73.6 | -39.6 |
| Net income | -73.6 | -38.3 |
| EPS (diluted, $ a share) | $-1.08 | $-0.65 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +5.9% |
|---|
10-Q filed with the SEC, NASDAQ: STOK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Stoke Therapeutics, Inc.: key numbers
- Share price
- $26.41Close, Nov 17
- Market cap
- $1.73B
- Shares outstanding
- 65.41MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Stoke Therapeutics, Inc.
All →Stoke Therapeutics CMO Barry Ticho Sells $185K of Stock
Barry Ticho, CMO, sold 6,995 shares of Stoke Therapeutics, Inc. at $26.38 a share, worth $185K in total on Nov 2, 2026. Shares held after the trade: 12,064 (-36.7%).
- Value
- $185K
- Shares
- 6,995
- Price
- $26.38
- Role
- CMO
- Holding change
- -36.7%
- Trade date
- Nov 2, 2026
Stoke Therapeutics Financial Results
Stoke Therapeutics reported Q3 2026 financial results, highlighting a cash position of $358.8 million which is expected to fund operations into early 2028. The company provided clinical updates on its Phase 3 EMPEROR study for Dravet syndrome, with a data readout anticipated in Q3 2027 and a planned NDA submission in H2 2027.
- Term
- Q3 2026
“The Phase 3 EMPEROR study of zorevunersen continues to progress well. Approximately 110 of 162 enrolled patients have completed their Week 28 visit when the primary endpoint of change in major motor seizure frequency is measured and approximately 20 are through Week 52, the end of the treatment period. All 20 of these patients are continuing into the open-label extension period of the study and to date, no patients have discontinued treatment.”
Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics
“Our second clinical program, STK-002, targets the protein haploinsufficiency that causes ADOA and therefore may have the potential to improve vision in people living with this severe genetic disease that often leads to blindness. Dosing in the first two cohorts is complete and dosing in the third cohort is underway with the fourth cohort expected to follow in early 2027.”
Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics
Stoke Therapeutics General Counsel & Corp Sec Jonathan Allan Sells $16.5K of Stock
Jonathan Allan, General Counsel & Corp Sec, sold 627 shares of Stoke Therapeutics, Inc. at $26.33 a share, worth $16.5K in total on Oct 2, 2026. Shares held after the trade: 20,598 (-3.0%).
- Value
- $16.5K
- Shares
- 627
- Price
- $26.33
- Role
- General Counsel & Corp Sec
- Holding change
- -3.0%
- Trade date
- Oct 2, 2026
Stoke Therapeutics CMO Barry Ticho Sells $27.5K of Stock
Barry Ticho, CMO, sold 1,051 shares of Stoke Therapeutics, Inc. at $26.16 a share, worth $27.5K in total on Oct 1, 2026. Shares held after the trade: 19,059 (-5.2%).
- Value
- $27.5K
- Shares
- 1,051
- Price
- $26.16
- Role
- CMO
- Holding change
- -5.2%
- Trade date
- Oct 1, 2026
Stoke Therapeutics Leadership Change
Stoke Therapeutics reported a change in its senior leadership or board of directors under Item 5.02. The filing indicates a departure, election, or appointment of a key officer or director, though specific names and roles were not provided in the metadata summary.